# Secukinumab

## Cosentyx 150mg prefilled pen

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | ICOSE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Indications        | Ankylosing spondylitis Plaque psoriasis (Moderate to Severe)， In patients who are candidates for systemic therapy or phototherapy Psoriatic arthritis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | SC， plaque psoriasis 300 mg weeks 0， 1， 2， 3， and 4， followed by every 4 weeks.( some patients may only need 150 mg) Psoriatic arthritis， ankylosing spondylitis， Non-radiographic axial spondyloarthritis， 150 mg weeks 0， 1， 2， 3， and 4， followed by 300 mg every 4 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Contraindications  | Hypersensitivity to secukinumab or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | [Common] Diarrhea (2.6% to 4.1% )， Nasopharyngitis (Ankylosing spondylitis， 2% or more ; plaque psoriasis， 11.4% to 12.3% ; psoriatic arthritis， 2% or more )， Upper respiratory infection (Ankylosing spondylitis， 2% or more ; plaque psoriasis， 2.5% to 3.2% ; psoriatic arthritis， 2% or more ) [Serious] Crohn's disease (Ankylosing spondylitis， 0.87% )， Crohn's disease， Exacerbation (Plaque psoriasis， 0.09% )， Inflammatory bowel disease， Ulcerative colitis (Ankylosing spondylitis， 0.5%; plaque psoriasis， 0.06% )， Ulcerative colitis， Exacerbation (Plaque psoriasis， 0.06% )， Anaphylaxis， Infectious disease (Ankylosing spondylitis， 31% ; plaque psoriasis (up to 12 weeks)， 28.7%; plaque psoriasis (up to 52 weeks)， 47.5% ; psoriatic arthritis， 29% ) |
| Pregnancy          | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

